Active clinical trials

Dry AMD is a chronic, progressive disease that can affect both eyes or asymmetrically. It causes blurred vision or reduced central vision.

Study for the Treatment of Geographic Atrophy Secondary to Dry AMD

• Phase : 3
• Duration: 2 and a half years
• Impact: International
• Treatment: Human immunoglobulin monoclonal antibody
• Cost to the patient: € 0
• Travel expenses: Covered

Recruitment open

Study for the treatment of GEOGRAPHIC ATROPHY associated with DRY AMD

• Phase: 2
• Duration: 18 months
• Impact: International
• Treatment: Intravitreal solution of avacincaptad pegol
• Cost to the patient: € 0
• Travel expenses: Covered

Recruitment open

Study for the treatment of Geographic Atrophy associated with dry AMD

• Phase 2
• Duration: 5 years (from the 1st year onwards, biannual follow-ups)
• Impact: International
• Treatment: single intravitreal dose 
• Cost for the patient: €0
• Travel expenses: Covered

Planned activation: July 2026

This is a condition that occurs in diabetic patients due to the accumulation of fluid in the retina.

Study for the treatment of Diabetic Macular Oedema (DMO)

• Phase 3
• Duration: 2 years
• Impact: International
• Treatment: Intravitreal  
• Cost to the patient: 0 € 
• Travel expenses: Covered

Planned activation: July 2026

Clinical Trial in Patients with Persistent Corneal Epithelial Defect (PCED)

Treatments for these patients are often limited to lubrication and protection, as there are no approved treatments available for PCED, and in many cases, patients do not respond to standard therapy.

Study for the treatment of moderate to severe PCED due to neurotrophic keratopathy

Phase: 2/3

• Duration: 56 to 84 days
• Impact: International
• Treatment: Ophthalmic gel
• Cost to patient: €0
• Travel expenses: Covered
   

Open recruitment

Post-market clinical follow-up (PMCF) study with a presbyopia-correcting intraocular lens in adults over 55 years of age.

• Duration: 3 years
• Impact: International
• Treatment: Implantation of a presbyopia-correcting intraocular lens for patients with cataracts
• Cost of lenses for the patient: €0
• Travel expenses: Covered

Recruitment closed

Clinical trial for the treatment of WET Age-Related Macular Degeneration (AMD)

Phase: 3 – B

• Duration: 18 months
• Impact: International
• Treatment: Gene therapy with recombinant viral vector. Administration via the subretinal route.
• Cost to the patient: €0 
• Travel expenses: Covered

Recruitment open

Study for the treatment of POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)

Phase: 4

• Duration: 2 years
• Impact: International
• Treatment: Intravitreal solution of faricimab
• Cost to the patient: €0
• Travel expenses: Covered

Recruitment open

Pivotal study for the treatment of wet AMD

Phase 2/3

• Duration: 24 months
• Impact: International
• Treatment: Intravitreal
• Cost for the patient: €0
• Travel expenses: Covered

Planned activation: June 2026

Trial for the treatment of wet Age-related Macular Degeneration (AMD)

Phase: 3

• Duration: 12 months
• Impact: International
• Tratamiento: Intravítreo
• Cost for the patient: €0
• Travel expenses: Covered

Planned activation: September 2026

Study for patients with subretinal hyperreflective material associated with neovascular membranes

Phase 4

• Duration: 30 months
• Impact: Nacional
• Treatment: Intravitreal
• Cost for the patient: €0 

Planned activation: July 2026